Raffield, Laura

Laura — thanks for the reminder! This was approved by CHS P&P on June 26th. My apologies, they typically send an automated response but I may have missed it while I was out of town. I hope this didn't hold anything up.

STEERING COMMITTEE: Penultimate Draft Manuscript Approved

Congratulations – the CHS Steering Committee has reviewed and approved this penultimate draft of your manuscript.

REVIEW COMMENTS:

The Committee's comments, if any, may be found by clicking on the relevant link at the top of your paper record.

Journal Submission Requirements:

1.   Please do not send the manuscript to journal until you have received final approval from NHLBI, if applicable (applies only to manuscripts with NHLBI employee authors)

2.   Before you sign a publication agreement or similar copyright transfer agreement, make sure that the agreement allows your CHS paper to be submitted to NIH PubMed Central (PMC) in accordance with the NIH Public Access Policy revised in 2008. It is also your responsibility to ensure that your paper is submitted to PMC, whether by you or directly by the journal.

3.   Please ensure that the CHS grant and contract numbers listed in your approved paper match the current **CHS Acknowledgment Guidelines**, and that they also appear in the final version submitted to journal for publication.

4.   Finally, please remember to update your online record when you submit your manuscript to journal and also also when you hear whether it has been accepted.

Best of luck with your journal submission!

For more information, please visit the **Publications Protocol** page.

Thank you.

On Jul 29, 2023, at 6:58 PM, Raffield, Laura <laura_raffield@unc.edu> wrote:

Hi Josh, Any news from P&P? Thanks!

Laura

From: Raffield, Laura <laura_raffield@unc.edu>
Sent: Monday, July 10, 2023 10:17 PM
To: Joshua C. Bis <joshbis@uw.edu>; Jiang, Minzhi <minzhi@live.unc.edu>
Subject: Re: TOPMed inflammation paper draft for review- proposal # 1854

Amazing thanks Josh!

Get Outlook for iOSFrom: Joshua C. Bis <joshbis@uw.edu>
Sent: Monday, July 10, 2023 5:12:18 PM
To: Jiang, Minzhi <minzhi@live.unc.edu>
Cc: Raffield, Laura <laura_raffield@unc.edu>
Subject: Re: TOPMed inflammation paper draft for review- proposal # 1854

thanks for the follow up and good luck movie the paper forward. I'll send you a confirmation from P&P when it comes through.

> On Jul 10, 2023, at 1:55 PM, Jiang, Minzhi <minzhi@live.unc.edu> wrote:
>
> Hi Josh,
>
> Thank you very much for your suggestions, and we have incorporated nearly all your suggestions and comments into our current version of draft (sent you on Jul/8th/2023). For effect allele frequencies, the reason why we reported according to 1000G rather than according to TOPMed is that TOPMed does not currently report allele frequencies by genetic ancestry cluster, as recommended by the recent NASEM guidelines, though this is a planned work in progress, or by local ancestry. We could use self-report race/ethnicity or HARE (which incorporates self-report race/ethnicity) pretty easily, as in many prior TOPMed publications, but this is not really concordant with NASEM guidelines and we think reviewers may push back, or we could derive genetic ancestry clusters specifically for this purpose, which is a fair bit of work. Therefore, we thought the most reasonable way forward was to report our overall EAF based on TOPMed and stratified EAF based on 1000G reference panel. Please feel free to email us if anything is unclear, and any suggestions and comments are very welcome.
>
> Best regards,
> Min-Zhi
>
>> On Jun 20, 2023, at 15:34, Joshua C. Bis <joshbis@uw.edu> wrote:
>>
>> I agree; the current version is good for P&P and I will submit it today.
>>
>>
>>
>>
>>> On Jun 20, 2023, at 12:14 PM, Raffield, Laura <laura_raffield@unc.edu> wrote:
>>>
>>> Thanks Josh for your careful review! Min-Zhi and I will work on getting these incorporated, we are meeting tomorrow to discuss these and other coauthor comments.
>>> If it is ok, I know we still have some work to do on how best to clearly present the science, but it would be great to start cohort review process if possible (I don't think any edits we make would substantially change paper re cohort decision making on acknowledgments, consent, authors, cohort description, etc)
>>> From: Joshua C. Bis <joshbis@uw.edu>

>>> Sent: Tuesday, June 20, 2023 2:41 PM
>>> To: Raffield, Laura <laura_raffield@unc.edu>; Paul Auer <paul.wl.auer@gmail.com>
>>> Cc: Bruce M Psaty <psaty@uw.edu>; Russell P Tracy <Russell.Tracy@uvm.edu>
>>> Subject: Re: TOPMed inflammation paper draft for review- proposal # 1854
>>> Laura & Paul — a few minor comments (in a separate doc).
>>>
>>> From my perspective, the current version is in great shape and I will submit to CHS P&P (copying Russ & Bruce for confirmation).
>>>
>>>
>>>
>>>> On Jun 15, 2023, at 9:59 AM, Bruce M Psaty <psaty@uw.edu> wrote:
>>>>
>>>> Laura and Paul,
>>>>   You have made a good start here. It is clear that you have conducted numerous high- quality analyses, and you have summarized the major findings.
>>>>   In my view, the names of the proteins that you studies belong in the main text even if you keep the data in S Table 2. Nowhere (that I can find) do you indicate what tests were used for the various proteins, presumably ELISAs. You might consider including the names of the cohorts as well.
>>>>   The text is sometimes hard to follow. For instance, with each protein, you detail the similarity of results in the published literature with the Olink and SomaLogic data. These "results" are not findings from your study, and may not even belong in the results section. You would do better, I think, to include table S8 in the main paper, perhaps in the discussion section. Some papers have published the correlation between ELISAs and aptamers, which are likely to affect the agreement for pQTLs. See Fig 2 in 19495.pdf.
>>>>   The abstract is an excellent summary of the findings. You might try to imitate its brevity in the summary of the results. For instance, just present the "final" conditional results. Given the structure of the tables, I might organize the results by single variant (Table 1) and then aggregate variants (Table 2). Use the text to highlight the results, which are provided in detail in the tables.
>>>>   It is not clear why the TM project for CHS is listed as "VTE" rather than "CHS."
>>>>   Once approved by coauthors, we can submit to CHS Publications.
>>>>   Apologies if my comments appear to be too critical of some fine work. Thanks for the opportunity to participate.
>>>>   Bruce
>>>> ============================
>>>> Bruce M. Psaty, MD, PhD
>>>> Professor, Medicine & Epidemiology
>>>> University of Washington
>>>> Cardiovascular Health Research Unit
>>>> 4333 Brooklyn Ave NE, Box 359458
>>>> Seattle, WA 98195-9458
>>>> Phone: 206/221-7775
>>>> Email: psaty@uw.edu   ============================
>>>> From: Raffield, Laura <laura_raffield@unc.edu>
>>>> Sent: Wednesday, June 14, 2023 9:01 AM
>>>> To: xihaoli@g.harvard.edu; Van Buren, Eric Daniel <evb@hsph.harvard.edu>; Adrienne M Stilp <amstilp@uw.edu>;regina.manansala@uantwerpen.be; Stephanie Gogarten <sdmorris@uw.edu>; zilli@iu.edu; Linda.Polfus@med.usc.edu;ssalimi@som.umaryland.edu; Josh Bis <joshbis@uw.edu>; Nathan D Pankratz <pankr018@umn.edu>; lryanek@jhmi.edu; 'Peter Durda' <peter.durda@med.uvm.edu>; 'Tracy, Russell P' <russell.tracy@med.uvm.edu>; ssr4n@virginia.edu; Rotter, Jerome <jrotter@lundquist.org>; Mitchell, Braxton

3

<bmitchel@som.umaryland.edu>; jlewis2@som.umaryland.edu; Bruce M Psaty <psaty@uw.edu>; 'Pratte, Katherine' <PratteK@NJHealth.org>; 'ED.SILVERMAN@CHANNING.HARVARD.EDU' <ed.silverman@channing.harvard.edu>; robert.kaplan <robert.kaplan@einsteinmed.edu>; Avery, Christy Leigh <christy_avery@unc.edu>; North, Kari E <kari_north@unc.edu>; rmathias@jhmi.edu; nfarada1@jhmi.edu; Lin, Honghuang <Honghuang.Lin@umassmed.edu>; biqi.wang@umassmed.edu; April P. Carson <apcarson@umc.edu>; Arnita F. Norwood <afnorwood@umc.edu>; Gibbs, Richard A. <agibbs@bcm.edu>; sormbrek@fredhutch.org; Lundin, Jessica <jlundin2@fredhutch.org>; Peters PhD, Ulrike <upeters@fredhutch.org>; DUPUIS@BU.EDU; Russell Tracy <Russell.Tracy@uvm.edu>;emelia@bu.edu; Alexander Reiner <apreiner@uw.edu>; Bowler, Russell <BowlerR@NJHealth.org>; Lin, Xihong <xlin@hsph.harvard.edu>

>>>> Cc: Jiang, Minzhi <minzhi@live.unc.edu>; sheilamariegaynor <sheilamariegaynor@gmail.com>; Paul Auer <pauer@mcw.edu>

>>>> Subject: TOPMed inflammation paper draft for review- proposal # 1854

>>>> Hi everyone, Thanks to all studies for nominating co-authors for this cross-cohort inflammation trait genetics paper, and to the Inflammation WG for their support of this multi-year project. We have prepared a draft paper describing freeze 8 TOPMed single variant and aggregate coding and noncoding mask tests across 21 inflammation biomarkers in up to 38,465 individuals, as was originally proposed around six years ago by Paul in proposal 1854. This paper is the result of several years of analysis and phenotype harmonization work by the working group. We are pleased to circulate an initial draft of our freeze 8 findings. We hope to submit to Human Molecular Genetics (alternate journal suggestions welcome as well).

>>>> We welcome your comments on how to best present our findings and improve the paper, and any needed edits, but would appreciate circulation of the paper to relevant cohort P&Ps at this time. Please double check your name and affiliation and cohort acknowledgments. Let Paul, Sheila, Min-Zhi and I know any questions you may have!

>>>> Best wishes, Laura

>>>> Laura Raffield Assistant Professor, Department of Genetics

>>>> 5042 Genetic Medicine Building

>>>> University of North Carolina at Chapel Hill

>>>> 120 Mason Farm Road

>>>> Chapel Hill, NC, 27599

>>>> laura_raffield@unc.edu

>>>> she / her / hers

>>>> <jcb-freeze 8 inflammation paper_06_14_2023.docx><freeze 8 inflammation paper_06_14_2023_bp.docx>

>>

>